Acucela: Acucela Announces Publication Assessing the Role of Emixustat Hydrochloride in Retinal Degeneration Treatment

Acucela Inc. Acucela a clinicalstage ophthalmology company and whollyowned subsidiary of Kubota Pharmaceutical Holdings Co. Ltd. Tokyo 4596 today announced the publication of an article concerning the companys investigational drug candidate emixustat hydro...